141 related articles for article (PubMed ID: 21733929)
1. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J
Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
[TBL] [Abstract][Full Text] [Related]
2. Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide.
Koivula MK; Ruotsalainen V; Björkman M; Nurmenniemi S; Ikäheimo R; Savolainen K; Sorva A; Risteli J
Ann Clin Biochem; 2010 Jan; 47(Pt 1):67-71. PubMed ID: 19940208
[TBL] [Abstract][Full Text] [Related]
3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
Tähtelä R; Thölix E
Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
6. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
7. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum.
Koivula MK; Risteli L; Risteli J
Clin Biochem; 2012 Aug; 45(12):920-7. PubMed ID: 22480789
[TBL] [Abstract][Full Text] [Related]
8. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
[TBL] [Abstract][Full Text] [Related]
9. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
Lüftner D; Jozereau D; Schildhauer S; Geppert R; Müller C; Fiolka G; Wernecke KD; Possinger K
Anticancer Res; 2005; 25(3A):1491-9. PubMed ID: 16033050
[TBL] [Abstract][Full Text] [Related]
10. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
11. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
12. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.
Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J
Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.
Chrapko BE; Nocuń A; Gołebiewska R; Jankowska H; Zaorska-Rajca J
Nucl Med Rev Cent East Eur; 2005; 8(2):100-4. PubMed ID: 16437394
[TBL] [Abstract][Full Text] [Related]
14. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
Kobayashi Y; Tokue A
Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
[TBL] [Abstract][Full Text] [Related]
16. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity.
Han B; Copeland M; Geiser AG; Hale LV; Harvey A; Ma YL; Powers CS; Sato M; You J; Hale JE
J Proteome Res; 2007 Nov; 6(11):4218-29. PubMed ID: 17924680
[TBL] [Abstract][Full Text] [Related]
17. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
18. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Koopmans N; de Jong IJ; Breeuwsma AJ; van der Veer E
J Urol; 2007 Sep; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
[TBL] [Abstract][Full Text] [Related]
19. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
